PURPOSE: Cancer-associated weight loss is associated with poor prognosis in advanced malignancy; however, its pretreatment prevalence and survival impact are inadequately described in large cohorts. Such data, stratified by tumor type and stage, may facilitate the optimal and timely allocation of complementary care, leading to improvements in patient survival and quality of life. METHODS: We performed a retrospective cohort study of 3,180 consecutively treated adult patients with lung or GI (including colorectal, liver, and pancreatic) cancer. Pretreatment cancer-associated weight loss was based on the international consensus definition of cachexia. Prevalence and survival impact of pretreatment cancer-associated weight loss were evaluated using the Kaplan-Meier method and compared using log-rank test. RESULTS: Cancer-associated weight loss was observed at the time of cancer diagnosis in 34.1% of patients. Pretreatment weight loss was documented in 17.6%, 25.8%, 36.6%, and 43.3% of stage I, II, III, and IV cancers, respectively. Wasting was common regardless of tumor type, with prevalence at diagnosis ranging from 27.3% in patients with colorectal cancer to 53.4% in patients with gastroesophageal cancer. Pretreatment weight loss was associated with reduced overall survival after adjusting for stage, size, grade, comorbidity, age, sex, and tobacco history (hazard ratio, 1.26; 95% CI, 1.13 to 1.39). CONCLUSION: Pretreatment cancer-associated weight loss is common, even in early-stage disease, and is independently associated with reduced survival. Minimal weight loss represents a clinically distinct entity with an associated overall survival intermediate to that of no weight loss and overt wasting. Early diagnosis and treatment of cancer-associated wasting offers a novel therapeutic avenue for reducing cancer mortality.
PURPOSE:Cancer-associated weight loss is associated with poor prognosis in advanced malignancy; however, its pretreatment prevalence and survival impact are inadequately described in large cohorts. Such data, stratified by tumor type and stage, may facilitate the optimal and timely allocation of complementary care, leading to improvements in patient survival and quality of life. METHODS: We performed a retrospective cohort study of 3,180 consecutively treated adult patients with lung or GI (including colorectal, liver, and pancreatic) cancer. Pretreatment cancer-associated weight loss was based on the international consensus definition of cachexia. Prevalence and survival impact of pretreatment cancer-associated weight loss were evaluated using the Kaplan-Meier method and compared using log-rank test. RESULTS:Cancer-associated weight loss was observed at the time of cancer diagnosis in 34.1% of patients. Pretreatment weight loss was documented in 17.6%, 25.8%, 36.6%, and 43.3% of stage I, II, III, and IV cancers, respectively. Wasting was common regardless of tumor type, with prevalence at diagnosis ranging from 27.3% in patients with colorectal cancer to 53.4% in patients with gastroesophageal cancer. Pretreatment weight loss was associated with reduced overall survival after adjusting for stage, size, grade, comorbidity, age, sex, and tobacco history (hazard ratio, 1.26; 95% CI, 1.13 to 1.39). CONCLUSION: Pretreatment cancer-associated weight loss is common, even in early-stage disease, and is independently associated with reduced survival. Minimal weight loss represents a clinically distinct entity with an associated overall survival intermediate to that of no weight loss and overt wasting. Early diagnosis and treatment of cancer-associated wasting offers a novel therapeutic avenue for reducing cancer mortality.
Authors: D Blum; G B Stene; T S Solheim; P Fayers; M J Hjermstad; V E Baracos; K Fearon; F Strasser; S Kaasa Journal: Ann Oncol Date: 2014-02-20 Impact factor: 32.976
Authors: Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos Journal: Lancet Oncol Date: 2011-02-04 Impact factor: 41.316
Authors: Jennifer S Temel; Joseph A Greer; Areej El-Jawahri; William F Pirl; Elyse R Park; Vicki A Jackson; Anthony L Back; Mihir Kamdar; Juliet Jacobsen; Eva H Chittenden; Simone P Rinaldi; Emily R Gallagher; Justin R Eusebio; Zhigang Li; Alona Muzikansky; David P Ryan Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni Journal: J Gastrointest Surg Date: 2008-03-18 Impact factor: 3.452
Authors: Oscar Arrieta; Rosa M Michel Ortega; Geraldine Villanueva-Rodríguez; Maria G Serna-Thomé; Diana Flores-Estrada; Consuelo Diaz-Romero; Cindy M Rodríguez; Luis Martínez; Karla Sánchez-Lara Journal: BMC Cancer Date: 2010-02-21 Impact factor: 4.430
Authors: Barbara S van der Meij; Coline P Schoonbeek; Egbert F Smit; Maurizio Muscaritoli; Paul A M van Leeuwen; Jacqueline A E Langius Journal: Br J Nutr Date: 2012-11-16 Impact factor: 3.718
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey Journal: Am J Med Date: 1980-10 Impact factor: 4.965
Authors: Blas A Guigni; Jos van der Velden; C Matthew Kinsey; James A Carson; Michael J Toth Journal: Am J Physiol Endocrinol Metab Date: 2019-11-05 Impact factor: 4.310
Authors: Nicole E Rich; Samuel Phen; Nirali Desai; Sukul Mittal; Adam C Yopp; Ju Dong Yang; Jorge A Marrero; Puneeth Iyengar; Rodney E Infante; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2021-09-20 Impact factor: 13.576
Authors: Santiago Olaechea; Bhavani S Gannavarapu; Anne Gilmore; Christian Alvarez; Puneeth Iyengar; Rodney Infante Journal: JCSM Clin Rep Date: 2021-09-05
Authors: Justin C Brown; Bette J Caan; Elizabeth M Cespedes Feliciano; Jingjie Xiao; Erin Weltzien; Carla M Prado; Candyce H Kroenke; Adrienne Castillo; Marilyn L Kwan; Jeffrey A Meyerhardt Journal: Am J Clin Nutr Date: 2021-06-01 Impact factor: 7.045
Authors: Jason Sadek; Derek T Hall; Bianca Colalillo; Amr Omer; Anne-Marie K Tremblay; Virginie Sanguin-Gendreau; William Muller; Sergio Di Marco; Marco Emilio Bianchi; Imed-Eddine Gallouzi Journal: EMBO Mol Med Date: 2021-06-07 Impact factor: 12.137